Summary
Acute isolated seizure, repetitive or recurrent seizures, and status epilepticus are all deemed medical emergencies. Mortality and worse neurologic outcome are directly associated with the duration of seizure activity. A number of recent reviews have described consensus statements regarding the pharmacologic treatment protocols for seizures when patients are in pre-hospital, institutional, and home-bound settings. Benzodiazepines, such as lorazepam, diazepam, midazolam, and clonazepam are considered to be medications of first choice. The rapidity by which a medication can be delivered to the systemic circulation and then to the brain plays a significant role in reducing the time needed to treat seizures and reduce opportunity for damage to the CNS. Speed of delivery, particularly outside of the hospital, is enhanced when transmucosal routes of delivery are used in place of an intravenous injection.
Intranasal transmucosal delivery of benzodiazepines is useful in reducing time to drug administration and cessation of seizures in the pre-hospital setting, when actively seizing patients arrive in the emergency room, and at home where care-givers treat their dependents. This review summarizes factors to consider when choosing a benzodiazepine for intranasal administration, including formulation and device considerations, pharmacology and pharmacokinetic/pharmacodynamic profiles. A review of the most relevant clinical studies in epilepsy patients will provide context for the relative success of this technique with a number of benzodiazepines and relatively less sophisticated nasal preparations. Neuropeptides delivered intranasally, crossing the blood-brain barrier via the olfactory system, may increase the availability of medications for treatment of epilepsy. Consequently, there remains a significant unmet medical need to serve the pharamcotherapeutic requirements of epilepsy patients through commercial development and marketing of intranasal antiepileptic products.
Article PDF
Similar content being viewed by others
References
Lowenstein DH, Alldredge BK. Status epilepticus. N Eng J Med 1998;338: 970–976.
Lowenstein DH, Bleck T, Macdonald RL. It’s time to revise the definition of status epilepticus. Epilepsia 1999;40: 120–122.
Wang HC, Chang WN, Chang HW, et al. Factors predictive of outcome in posttraumatic seizures. J Trauma 2008;64: 883–888.
Stavem K, BJornaes H, Langmoen IA. Long-term seizures and quality of life after epilepsy surgery compared with matched controls. Neurosurgery 2008;62: 326–334.
Logroscino G, Hessdorffer DC, Cascino G, et al. Time trends in incidence, mortality, and case-fatality after first episode of status epilepticus. Epilepsia 2001;42: 1031–1035.
Feen ES, Bershad EM, Suarez JI. Status Epilepticus. South Med J 2008;101: 400–406.
Pang T, Hirsch L. Treatment of convulsive and nonconvulsive status epilepticus. Cur Treat Options Neurol 2005;7: 247–259.
Smith B. Treatment of status epilepticus. Neurol Clin 2001;19: 347–369.
Ericksson K, Kalviainen R. Pharmacologic management of convulsive status epilepticus in childhood. Expert Rev Neurotherapeutics 2005;5: 777–783.
Wolfe T, Macfarlane T. Intranasal midazolam therapy for pediatric status epilepticus. Am J Emerg Med 2006;24: 343–346.
Meierkord H, Engelsen B, Gocke K, et al. EFNS guideline on the management of status epilepticus. Eur J Neurol 2006;13: 445–450.
Prasad K, Krishman P, Al-Roomi K, et al. Anticonvulsant therapy for status epilepticus. Br J Clin Pharmacol 2007;63: 640–647.
Illum L. Nasal Clearance in Health and Disease. J Aerosol Med 2006;19: 92–99.
Merkus P, Ebbens FA, Muller B, Fokkens WJ. Influence of anatomy and head position on intranasal drug deposition. Eur Arch Otorhinolaryngol 2006;263: 827–832.
Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000;11: 1–18.
Illum L. Is nose to brain transport of drugs a reality? JPP 2004; 56: 3–17.
Merkus F, van den Berg MP. Can nasal drug delivery bypass the blood-brain barrier? Questioning the direct transport theory. Drugs 2007;8: 133–144.
Constantino HR, Illum L, Brandt G, et al. Intl J Pharmaceutics 2007;337: 1–24.
Davis GA, Rudy AC, Archer SA, Wermeling DP, McNamara PJ. Effect of fluticasone propionate nasal spray on bioavailability of hydromorphone hydrochloride in patients with allergic rhinitis. Pharmacotherapy 2004;24: 26–32.
Davis GA, Rudy AC, Archer SM, Wermeling DP, McNamara PJ. Bioavailability and pharmacokinetics of intranasal hydromorphone in patients experiencing vasomotor rhinitis. Clin Drug Invest 2004; 24: 1–7.
Holsti M, Sill B, Firth S, et al. Prehospital intranasal midazolam for the treatment of pediatric seizures. Ped Emerg Care 2007;23: 148–153.
Rudy AC, Coda BA, Archer SM, Wermeling DP. A multiple dose phase 1 study of intranasal hydromorphone hydrochloride in healthy volunteers. Anesth Analg 2004;99: 1379–1386.
Van den Donk HJ, van den Huervel AG, Zuidema J, Merkus FW. The effects of nasal drops and their additives on human nasal mucociliary clearance. Rhinology 1982;20: 127–137.
Kubek MJ, Domb AJ, Veronesi MC. Attenuation of kindled seizures by intranasal delivery of neuropeptide-loaded nanoparticles. Neurotherapeutics 2009;6: 359–371.
Loftsson T, Gudmundsdottir H, Sigurjonsdottir JF, et al. Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray. Int J Pharm 2001;212: 29–40.
Knoester PD, Jonker DM, Van Der Hoeven RT, et al. Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. Br J Clin Pharmacol 2002;53: 501–507.
Gudmundsdottir H, Sigurjonsdottir JF, Masson M, et al. Intranasal administration of midazolam in a cyclodextrin based formulation: bioavailability and clinical evaluation in humans. Pharmazie 2001; 56: 963–966.
Dale O, Nilsen T, Loftsson T. Intranasal midazolam: a comparison of two delivery devices in human volunteers. J Pharmacy Pharmacol 2006;58: 1311–1318.
Burstein AH, Modica R, Hatton M, et al. Pharmacokinetics and pharmacodynamics of midazolam after intranasal administration. J Clin Pharmacol 1997;37: 711–718.
Wermeling D, Record K, Kelly T, et al. Pharmacokinetics and pharamcodynamics of a new intranasal midazolam formulation in healthy volunteers. Anesth Analg 2006;103: 344–349.
Schols-Hendriks MWG, Lohman JJHM, Janknegt R, et al. Absorption of clonazepam after intranasal and buccal administration. Br J Clin Pharmacol 1995;39: 449–451.
Lindhardt K, Gizurarson S, Stefansson SB, et al. Electroencephalographic effects and serum concentrations after intranasal and intravenous administration of diazepam to healthy volunteers. Br J Clin Pharmacol 2001;52: 521–527.
Lau SWJ, Slattery JT. Intl J Pharmaceutics. Absorption of diazepam and lorazepam following intranasal administration. Int J Pharmaceutics 1989;54: 171–174.
Wermeling DP, Miller JL, Archer SM, et al. Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration. J Clin Pharmacol 2001;41: 1225–1231.
Greenblatt D, Gan L, Harmatz, et al. Pharmacokinetics and pharmacodynamics of single-dose triazolam: EEG compared with digital symbol substitution test. Br J Clin Pharmacol 2005;60: 244–248.
O’Regan M, Brown J, Clarke M. Nasal rather than rectal benzodiazepines in the management of acute childhood seizures. Develop Med and Child Neurol 1996;38: 1037–1045.
Mittal P, Manohar R, Rawat A. Comparative study of intranasal midazolam and intravenous diazepam sedation for procedures and seizures. Ind J Pediatrics 2006;73: 975–978.
Mahmoudian T, Zadeh M. Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children. Epilepsy Behav 2004;5: 253–255.
Lahat E, Goldman M, Barr J, et al. Comparison of intranasal midazolam with intravenous diazepam in treating febrile seizures in children: prospective randomized study. BMJ 2000;321: 83–87.
Bhattacharyya M, Kalra V, Gulati S. Intranasal midazolam vs rectal diazepam in acute childhood seizures. Pediatric Neurology 2006;34: 355–359.
Wilson MT, Macleod S, O’Regan ME. Nasal/buccal midazolam use in the community. Arch Dis Child 2004;89: 50–51.
Harbord MG, Kyrkou NE, Kyrkou MR, Kay D, Coulthard KP. Use of intranasal midazolam to treat acute seizures in paediatric community settings. J Paediatr Child Health 2004;40: 556–558.
Jeannet PY, Roulet E, Maeder-Ingvar M, Gehri M, Jutzi A, Deonna T. Home and hospital treatment of acute seizures in children with nasal midazolam. Eur J Paediatr Neurol 1999;3: 73–77.
Ahmad S, Ellis J, Kamwendo H, Molyneux E. Efficacy and safety of intranasal lorazepam versus intramuscular paraldehyde for protracted convulsions in children: an open label trial. Lancet 2006; 367: 1591–1597.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wermeling, D.P. Intranasal delivery of antiepileptic medications for treatment of seizures. Neurotherapeutics 6, 352–358 (2009). https://doi.org/10.1016/j.nurt.2009.01.002
Issue Date:
DOI: https://doi.org/10.1016/j.nurt.2009.01.002